1. Home
  2. CALC vs NDLS Comparison

CALC vs NDLS Comparison

Compare CALC & NDLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CALC
  • NDLS
  • Stock Information
  • Founded
  • CALC 2011
  • NDLS 1995
  • Country
  • CALC United States
  • NDLS United States
  • Employees
  • CALC N/A
  • NDLS N/A
  • Industry
  • CALC Biotechnology: Pharmaceutical Preparations
  • NDLS Restaurants
  • Sector
  • CALC Health Care
  • NDLS Consumer Discretionary
  • Exchange
  • CALC Nasdaq
  • NDLS Nasdaq
  • Market Cap
  • CALC 22.9M
  • NDLS 32.9M
  • IPO Year
  • CALC N/A
  • NDLS 2013
  • Fundamental
  • Price
  • CALC $2.13
  • NDLS $0.90
  • Analyst Decision
  • CALC Strong Buy
  • NDLS Strong Buy
  • Analyst Count
  • CALC 2
  • NDLS 2
  • Target Price
  • CALC $14.50
  • NDLS $3.00
  • AVG Volume (30 Days)
  • CALC 38.7K
  • NDLS 223.1K
  • Earning Date
  • CALC 08-11-2025
  • NDLS 08-06-2025
  • Dividend Yield
  • CALC N/A
  • NDLS N/A
  • EPS Growth
  • CALC N/A
  • NDLS N/A
  • EPS
  • CALC N/A
  • NDLS N/A
  • Revenue
  • CALC N/A
  • NDLS $495,670,000.00
  • Revenue This Year
  • CALC N/A
  • NDLS $5.37
  • Revenue Next Year
  • CALC N/A
  • NDLS $0.68
  • P/E Ratio
  • CALC N/A
  • NDLS N/A
  • Revenue Growth
  • CALC N/A
  • NDLS N/A
  • 52 Week Low
  • CALC $1.42
  • NDLS $0.55
  • 52 Week High
  • CALC $5.97
  • NDLS $1.83
  • Technical
  • Relative Strength Index (RSI)
  • CALC 48.14
  • NDLS 61.53
  • Support Level
  • CALC $1.59
  • NDLS $0.66
  • Resistance Level
  • CALC $1.69
  • NDLS $0.82
  • Average True Range (ATR)
  • CALC 0.15
  • NDLS 0.08
  • MACD
  • CALC 0.01
  • NDLS 0.02
  • Stochastic Oscillator
  • CALC 46.51
  • NDLS 93.68

About CALC CalciMedica Inc.

CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.

About NDLS Noodles & Company

Noodles & Co is a restaurant concept offering lunch and dinner within the fast-casual segment of the restaurant industry. The company's menu includes a variety of cooked-to-order dishes, including noodles and pasta, soups, salads and appetizers. The company also provides dining, pick-up and delivery services.

Share on Social Networks: